SAN DIEGO--(BUSINESS WIRE)--MBrace™ Therapeutics, Inc. (“MBrace”), a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, announced the completion of an $85 million Series B financing, bringing the company’s total raised to $110 million.

圣地亚哥-（商业信息）-MBrace™ Therapeutics，Inc.（“MBrace”）是一家私营生物制药公司，致力于通过开发针对新型肿瘤学目标的抗体-药物偶联物（ADC）来改善癌症患者的生活，宣布完成8500万美元的B系列融资，使该公司总数增至1.1亿美元。

Funds will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101..

资金将用于支持临床开发计划，包括先导研究ADC，MBRC-101的首次人体临床试验。。

TPG led the round, investing in the company through its dedicated life sciences fund, TPG Life Sciences Innovations (TPG LSI), and its multi-sector impact strategy, The Rise Fund. The round also included new investors Avidity Partners and Cowen Healthcare Investments, as well as existing Series A investors, Venrock and Alta Partners..

TPG领导该轮，通过其专门的生命科学基金，TPG生命科学创新（TPG LSI）及其多部门影响战略Rise基金对公司进行投资。该轮还包括新投资者Avidity Partners和Cowen Healthcare Investments，以及现有的A系列投资者Venrock和Alta Partners。。

Originally founded in June 2020 by Isan Chen, M.D., Renata Pasqualini, Ph.D., and Wadih Arap, M.D., Ph.D., MBrace is focused on developing lead ADC candidate, MBRC-101, and is advancing its proprietary SPARTA approach, which accelerates the development of antibody-based drugs for personalized medicine.

MBrace最初成立于2020年6月，由Isan Chen博士，Renata Pasqualini博士和Wadih Arap博士，MBrace专注于开发ADC领先候选药物MBRC-101，并正在推进其专有的SPARTA方法，该方法加速了基于抗体的个性化医疗药物的开发。

MBrace has generated extensive preclinical data on novel drug candidates in-licensed from Rutgers, The State University of New Jersey..

MBrace已经获得了新泽西州立大学罗格斯大学许可的新型候选药物的广泛临床前数据。。

“This investor syndicate shares our confidence in the potential of our novel ADC therapeutics pipeline to meaningfully impact the treatment of people with difficult-to-treat cancers,” said Isan Chen, M.D., president and chief executive officer at MBrace. “This additional capital will enable us to advance our clinical programs, including entering Phase 1 study with MBRC-101 before end of year and progressing our differentiated approach to the clinical development of our additional ADC pipeline candidates.

MBrace总裁兼首席执行官Isan Chen博士说：“这个投资者集团分享了我们对新型ADC治疗管道的潜力的信心，以有意义地影响治疗难治性癌症患者的治疗。”。“这项额外的资金将使我们能够推进我们的临床项目，包括在年底之前进入MBRC-101的第一阶段研究，并推进我们的差异化方法来临床开发额外的ADC管道候选人。

We are well poised to make significant progress in the near-term and continue on a positive growth trajectory.”.

我们已做好准备，在近期取得重大进展，并继续保持积极的增长轨迹。

MBRC-101 targets the EphA5 receptor tyrosine kinase, which is present in multiple cancers including, but not limited to, breast, non-small cell lung (NSCLC), colorectal, gastric, and pancreatic cancers. The MBrace team will present preclinical data for MBRC-101 at the San Antonio Breast Cancer Symposium on December 7, 2023..

MBRC-101靶向EphA5受体酪氨酸激酶，该激酶存在于多种癌症中，包括但不限于乳腺癌，非小细胞肺癌（NSCLC），结直肠癌，胃癌和胰腺癌。MBrace团队将于2023年12月7日在圣安东尼奥乳腺癌研讨会上介绍MBRC-101的临床前数据。。

“We are thrilled to support MBrace in improving the lives of cancer patients with significant unmet clinical need,” said Carolyn Ng, Ph.D., Business Unit Partner with TPG LSI. “Powered by a team of seasoned drug developers, with support from an accomplished Board with great collective experience building successful pharmaceutical companies, MBrace is deeply committed and well positioned to realize its vision of bringing innovative first-in-class ADC therapeutics to the clinic.”.

TPG LSI业务部门合作伙伴Carolyn Ng博士说：“我们很高兴支持MBrace改善临床需求未得到满足的癌症患者的生活。”。“由一批经验丰富的药物开发商提供支持，在一个有着丰富集体经验的有成就的董事会的支持下，成功的制药公司，MBrace致力于实现将创新的一流ADC疗法带入临床的愿景“。

The company also welcomed Christopher LeMasters, MBA, CEO of XinThera, to the MBrace Board of Directors as an independent director. XinThera is a subsidiary of Gilead Pharmaceuticals that is focused on small molecule discovery and development of oncology and immunology therapeutics. LeMasters brings decades of experience in oncology therapeutics to MBrace.

该公司还欢迎XinThera首席执行官MBA的Christopher LeMasters作为独立董事加入MBrace董事会。XinThera是Gilead Pharmaceuticals的子公司，专注于小分子发现和肿瘤学和免疫学治疗的开发。LeMasters为肿瘤治疗带来了数十年的经验。

In addition to LeMasters, Ng and Monal Mehta, Ph.D., of Avidity Partners will also join the Board in conjunction with the financing. These additions complement the deep expertise of existing board members Bob More of Alta Partners and Racquel Bracken of Venrock..

除了LeMasters之外，Avidity合作伙伴的Ng和Monal Mehta博士也将与融资一起加入董事会。这些补充补充了现有董事会成员Bob More（Alta Partners）和Venrock的Racquel Bracken的深刻专业知识。。

About MBrace Therapeutics

关于MBrace疗法

MBrace is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutic agents for patients with cancer. MBrace develops innovative treatments for cancer patients by developing novel antibody-drug conjugates against targets identified using technology pioneered by its founders.

MBrace是一家临床阶段制药公司，致力于为癌症患者开发和商业化新型治疗药物。MBrace通过开发针对使用其创始人开创的技术鉴定的靶标的新型抗体-药物缀合物，为癌症患者开发创新疗法。

MBrace is headquartered in San Diego, CA, with research facilities at The Thomas O. Daniel Research Incubator and Collaboration Center at Bristol Myers Squibb in Summit, NJ. For additional information, please visit MBrace’s website at http://www.mbracetrx.com..

MBrace总部设在加利福尼亚州圣地亚哥，在新泽西州峰会的百时美施贵宝的Thomas O.Daniel研究孵化器和合作中心设有研究设施。欲了解更多信息，请访问MBrace的网站http://www.mbracetrx.com..